

Resource Summary Report

Generated by [NIF](#) on Sep 13, 2026

C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt

RRID:IMSR_GPT:T037657

Type: Organism

Proper Citation

RRID:IMSR_GPT:T037657

Organism Information

URL: https://en.gempharmatech.com/product/details100035_3719035.html

Proper Citation: RRID:IMSR_GPT:T037657

Description: Mus musculus with name C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt from IMSR.

Species: Mus musculus

Notes: gene symbol note: angiotensin I converting enzyme 2; coisogenic strain: ACE2;H11

Affected Gene: angiotensin I converting enzyme 2

Catalog Number: GPT:T037657

Database: GemPharmatech

Database Abbreviation: GPT

Availability: embryo

Organism Name: C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt

Record Creation Time: 20250513T054339+0000

Record Last Update: 20260912T061032+0000

Ratings and Alerts

No rating or validation information has been found for C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt.

No alerts have been found for C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: GemPharmatech

Usage and Citation Metrics

We found 447 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu X, et al. (2026) SARS-CoV-2 directly infects the inner ear and causes hearing dysfunction. *Cell reports*, 45(4), 117251.

Wang M, et al. (2026) Impaired VLCFA-peroxisome-mediated intestinal epithelial repair causes gastrointestinal sequelae of long COVID. *Developmental cell*.

Yehia A, et al. (2026) SARS-CoV-2 Spike Protein Induces Time-Dependent and Brain-Region-Specific Alterations in Ferroptosis Markers: A Preliminary Study in K18-hACE2 Mice. *International journal of molecular sciences*, 27(3).

Pagni RL, et al. (2026) An innovative nasal nanovaccine against SARS-CoV-2 induces systemic and upper airway immunity controlling viral replication. *NPJ vaccines*, 11(1).

Vu MN, et al. (2026) Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza. *Molecular therapy. Nucleic acids*, 37(2), 102873.

Li S, et al. (2026) Rapid and potent induction of protective mucosal immunity against SARS-CoV-2 by an adenovirus-vectored nanoparticle vaccine. *Journal of nanobiotechnology*, 24(1).

Wang J, et al. (2026) Redirection of SARS-CoV-2 to phagocytes by intranasal sACE2-Fc as a universal decoy confers complete prophylactic protection. *eLife*, 14.

Solopov PA, et al. (2026) Targeting PTP4A3 with KVX-053 mitigates alcohol-amplified SARS-CoV-2 spike protein-induced acute lung injury. *Frontiers in pharmacology*, 17, 1862783.

Matsui Y, et al. (2026) CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion. *iScience*, 29(4), 115334.

Wang M, et al. (2026) Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants. *Nature communications*, 17(1), 1753.

Li R, et al. (2026) Natural Selection-Guided ACE2-Targeted Molecular Imaging: A New Paradigm for PET Tracer Development. *Chemical & biomedical imaging*, 4(1), 64.

Marcos-Villar L, et al. (2026) Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection. *Frontiers in immunology*, 17, 1787877.

Russ A, et al. (2026) Live attenuated vaccination protects aged chimeric ACE2 mice from severe SARS-CoV-2 pathogenicity in vivo. *PLoS pathogens*, 22(4), e1014167.

Li Q, et al. (2026) A subunit vaccine for multiple respiratory viruses. *Science advances*, 12(26), eaea3227.

Yang Y, et al. (2026) Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes. *Emerging microbes & infections*, 15(1), 2631206.

Kong W, et al. (2026) Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. *Journal of virology*, 100(4), e0027026.

Shan H, et al. (2026) Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model. *Acta pharmaceutica Sinica. B*, 16(1), 387.

Konrath KM, et al. (2026) Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization. *PLoS pathogens*, 22(2), e1013905.

Subramaniam S, et al. (2026) Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2. *Blood vessels, thrombosis & hemostasis*, 3(1), 100128.

Botta D, et al. (2026) Intranasal Immunization with Live-Attenuated RSV-Vectored SARS-CoV-2 Vaccines Elicits Antigen-Specific Systemic and Mucosal Immunity and Protects Against Viral Challenge and Natural Infection. *Vaccines*, 14(5).